Original Article
The profile of IL-4, IL-5, IL-10 and GATA3 in patients with LRBA deficiency and CVID with no known monogenic disease: Association with disease severity
G. Azizia,b,c,d, Y. Bagherie,f, R. Yazdanic, M. Zaki-Dizajig, M. Jameeh, F. Jadidi-Niaraghi,j, A.N. Kamalik, H. Abolhassanic,l, A. Aghamohammadic,
Corresponding author
a Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
b Department of Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
c Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
d Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Tehran, Iran
e Clinical Research Development Unit (CRDU), 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
f Department of Allergy and Clinical Immunology, Iran University of Medical Sciences, Tehran, Iran
g Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
h Student Research Committee, Alborz University of Medical Sciences, Alborz, Iran
i Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
j Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
k CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran
l Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden
Ver másRead
3734
Timeswas read the article
656
Total PDF
3078
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 25 | 0 | 25 |
| 2025 11 | 65 | 14 | 79 |
| 2025 10 | 38 | 13 | 51 |
| 2025 9 | 47 | 11 | 58 |
| 2025 8 | 59 | 11 | 70 |
| 2025 7 | 85 | 6 | 91 |
| 2025 6 | 73 | 10 | 83 |
| 2025 5 | 62 | 6 | 68 |
| 2025 4 | 62 | 5 | 67 |
| 2025 3 | 87 | 7 | 94 |
| 2025 2 | 73 | 8 | 81 |
| 2025 1 | 55 | 4 | 59 |
| 2024 12 | 58 | 7 | 65 |
| 2024 11 | 50 | 5 | 55 |
| 2024 10 | 38 | 8 | 46 |
| 2024 9 | 43 | 12 | 55 |
| 2024 8 | 36 | 14 | 50 |
| 2024 7 | 30 | 7 | 37 |
| 2024 6 | 54 | 5 | 59 |
| 2024 5 | 42 | 6 | 48 |
| 2024 4 | 64 | 7 | 71 |
| 2024 3 | 60 | 10 | 70 |
| 2024 2 | 97 | 25 | 122 |
| 2024 1 | 59 | 17 | 76 |
| 2023 12 | 49 | 18 | 67 |
| 2023 11 | 50 | 10 | 60 |
| 2023 10 | 92 | 28 | 120 |
| 2023 9 | 81 | 15 | 96 |
| 2023 8 | 72 | 24 | 96 |
| 2023 7 | 70 | 23 | 93 |
| 2023 6 | 75 | 9 | 84 |
| 2023 5 | 115 | 6 | 121 |
| 2023 4 | 114 | 7 | 121 |
| 2023 3 | 70 | 3 | 73 |
| 2023 2 | 40 | 7 | 47 |
| 2023 1 | 37 | 8 | 45 |
| 2022 12 | 26 | 10 | 36 |
| 2022 11 | 33 | 24 | 57 |
| 2022 10 | 34 | 17 | 51 |
| 2022 9 | 34 | 9 | 43 |
| 2022 8 | 37 | 11 | 48 |
| 2022 7 | 31 | 11 | 42 |
| 2022 6 | 41 | 18 | 59 |
| 2022 5 | 36 | 12 | 48 |
| 2022 4 | 37 | 10 | 47 |
| 2022 3 | 37 | 10 | 47 |
| 2022 2 | 21 | 7 | 28 |
| 2022 1 | 42 | 4 | 46 |
| 2021 12 | 34 | 14 | 48 |
| 2021 11 | 26 | 11 | 37 |
| 2021 10 | 49 | 14 | 63 |
| 2021 9 | 34 | 12 | 46 |
| 2021 8 | 29 | 5 | 34 |
| 2021 7 | 38 | 12 | 50 |
| 2021 6 | 31 | 8 | 39 |
| 2021 5 | 34 | 11 | 45 |
| 2021 4 | 78 | 13 | 91 |
| 2021 3 | 35 | 11 | 46 |
| 2021 2 | 22 | 11 | 33 |
| 2021 1 | 18 | 10 | 28 |
| 2020 12 | 2 | 0 | 2 |
| 2020 7 | 0 | 1 | 1 |
| 2019 7 | 3 | 0 | 3 |
| 2019 5 | 7 | 0 | 7 |
| 2019 3 | 0 | 2 | 2 |
| 2019 2 | 2 | 2 | 4 |
Show all
